Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic Diversity in Drug Transporters: Impact in African Populations.

Clinical and translational science·2020

Same author

New paradigm for expediting drug development in Asia.

Drug discovery today·2020

Same author

Introducing Project Africa GRADIENT.

Drug discovery today·2019

Same author

Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment .

International journal of clinical pharmacology and therapeutics·2017

Same author

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.

EBioMedicine·2017

Same author

Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects .

International journal of clinical pharmacology and therapeutics·2016

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

PK/PD modelling and simulations: utility in drug development.

¹Novartis Pharma AG, WSJ-210.6.29, CH-4056 Basel, Switzerland. iris.rajman@novartis.com

Drug Discovery Today

|April 15, 2008

Summary

Pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation accelerates drug development by assessing efficacy and safety. Embracing PK/PD modelling across the industry can reduce failures and streamline regulatory processes.

Related Experiment Videos

Last Updated: Jul 6, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

Pharmacology
Drug Development
Biostatistics

Background:

Pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation is an applied science.
It offers a faster and more cost-effective approach to evaluating new drug candidates.
This methodology spans from preclinical research to all clinical phases.

Purpose of the Study:

To highlight the utility of PK/PD modelling and simulation in drug development.
To emphasize its role in improving efficiency and reducing costs.
To advocate for broader adoption and education in the field.

Main Methods:

Application of PK/PD modelling and simulation across various stages of drug development.
Analysis of data to predict drug efficacy and safety profiles.
Integration of modelling results into decision-making processes.

Main Results:

PK/PD modelling can provide timely answers regarding drug efficacy and safety.
Optimal utilization leads to a reduction in compound and study failures.
It can decrease the number of studies required for drug registration.

Conclusions:

PK/PD modelling and simulation is a valuable tool for efficient drug development.
Widespread industry and regulatory agency adoption is crucial for its full potential.
Increased educational initiatives are necessary to support its implementation.